The Priority Review

Tag

KEYNOTE-522

1 story

  1. Clinical trials

    Merck posts results of Phase III KEYNOTE-522 trial in triple negative breast cancer

    The study enrolled 1,174 participants and compared pembrolizumab plus chemotherapy to placebo plus chemotherapy as neoadjuvant therapy, followed by pembrolizumab or placebo as adjuvant therapy. Results were first posted on ClinicalTrials.gov on October 22, 2026.